Roche consensus stays cautious, shares trade below recent highs on SIX
Published on 06/26/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 12:39.
Roche Holding AG (CH0012032048) sits in the analyst spotlight this Friday with a broadly stable consensus while the bearer shares trade on SIX Swiss Exchange slightly below recent highs. MarketScreener data show the stock at around 333 Swiss francs today with a muted daily change.
What the analyst consensus shows
According to MarketScreener, around 30 analysts cover Roche, with the average recommendation currently in the Hold range and a moderate spread between Buy and Sell votes. The consensus 12?month price target stands noticeably above the latest SIX quote, implying upside but with cautious conviction. The same overview points to a forward price-earnings ratio in the high-teens area, consistent with large-cap European pharma peers such as Novartis.
Dividend metrics also underline a defensive profile. Hargreaves Lansdown cites a dividend of 9.80 Swiss francs per share for 2026, translating into a yield just under 3 percent at recent price levels, with an ex-dividend date on 12 March and payment on 16 March 2026. This sits in line with Roche's established policy of regular payouts and positions the stock as income-relevant for SMI investors alongside Novartis and Nestlé.
How ratings and targets differ
The distribution of ratings leans toward neutral stances. MarketScreener lists a mix of Buy, Hold and Sell recommendations, with no single view dominating and several large houses smoothing out extremes in sentiment. Recent target updates have fine-tuned rather than radically changed views, reflecting the mature nature of Roche's core franchises and late-stage pipeline.
From a valuation standpoint, the forward P/E in the high-teens and an enterprise-value-to-sales multiple in the mid-single digits leave Roche trading at a modest premium to some European healthcare names but below high-growth US biotech multiples. Investors thus pay for scale and balance sheet strength rather than for aggressive growth promises, a pattern that fits the cautious consensus wording from several analysts in recent months.
All news and analysis on the Roche shares
Further background, ad-hoc releases and price data on Roche can be found in the dedicated topic overview and in the company’s investor relations materials.
The medicines behind the earnings
Roche generates most of its sales with prescription medicines and diagnostics. Key oncology products such as Perjeta for HER2?positive breast cancer and Avastin for various solid tumors still contribute materially, complemented by immunology drugs and a broad diagnostics portfolio in areas like molecular testing and diabetes care.
Where the shares trade today
The Roche shares (CH0012032048) trade on 2026-06-26, 12:07 on SIX Swiss Exchange at around 333.30 Swiss francs.
Key data on the Roche shares
- Company: Roche Holding AG
- ISIN: CH0012032048
- WKN: 855167
- Ticker: ROG
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-26, 12:07): 333.30 CHF
- Market cap: 272.23 billion CHF (as of 2026-06-26)
- Sector / industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: SMI, Stoxx Europe 50
- Next earnings date: 2026-07-25
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
